Biotest Aktiengesellschaft announced preliminary guidance for the full year of 2017. For the period, the company generated revenue of EUR 378.1 million in the continuing operations, compared to EUR 408.0 million in the previous year. The main reason for the decline in revenue was the recall of human albumin. The former EBIT guidance, which included the continuing and discontinued US operations, was reduced on April 26, 2017 after the albumin recall from EUR 46 to EUR 48 million to EUR 16 to EUR 23 million for the 2017 financial year. This guidance, which included the earnings contribution of the US companies, was reached with EUR 18 million. The LBIT in continuing operations amounted to EUR 9.3 million in the 2017 financial year after EUR 35.2 million in the previous year. One-off expenses from inventory write-offs, penalties and other costs for the recall of various batches of human albumin as well as legal and consulting fees in connection with the takeover by Tiancheng (Germany) Pharmaceutical Holdings AG, Munich, Germany in the amount of EUR 37.7 million had a negative impact on the EBIT of continuing operations.